{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:02:50Z","timestamp":1768309370665,"version":"3.49.0"},"reference-count":41,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.26633\/rpsp.2024.81","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:41:44Z","timestamp":1734349304000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Seropositividad de IgG para los virus del sarampi\u00f3n y de la rub\u00e9ola en la era poseliminaci\u00f3n, Costa Rica, 2012-2023"],"prefix":"10.26633","volume":"48","author":[{"given":"Ana Isela","family":"Ruiz-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Instituto Costarricense de Investigaci\u00f3n y Ense\u00f1anza en Nutrici\u00f3n y Salud, San Jos\u00e9, Costa Rica."},{"name":"aruiz@inciensa.sa.cr"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aar\u00f3n","family":"Ag\u00fcero-Zumbado","sequence":"additional","affiliation":[{"name":"Ministerio de Salud, San Jos\u00e9, Costa Rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandra","family":"Abarca-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Caja Costarricense de Seguro Social, San Jos\u00e9, Costa Rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Duron","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Soto-Garita","sequence":"additional","affiliation":[{"name":"Instituto Costarricense de Investigaci\u00f3n y Ense\u00f1anza en Nutrici\u00f3n y Salud, San Jos\u00e9, Costa Rica."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Rey-Benito","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Panamericana de la Salud, Washington D.C., Estados Unidos de Am\u00e9rica."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11167","reference":[{"key":"ref1","unstructured":"Ministerio de Salud. Protocolo de Vigilancia epidemiol\u00f3gica para el Sarampi\u00f3n y Rubeola, 2015. San Jos\u00e9 de Costa Rica: Ministerio de Salud; 2015. Disponible en: https:\/\/www.ministeriodesalud.go.cr\/index.php\/biblioteca-de-archivos-left\/documentos-ministerio-de-salud\/vigilancia-de-la-salud\/normas-protocolos-guias-y-lineamientos\/inmunoprevenibles\/1832-protocolo-de-vigilancia-sarampion-rubeola\/file"},{"key":"ref2","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Sarampi\u00f3n. Washington D.C.: OPS. Disponible en: https:\/\/www.paho.org\/es\/temas\/sarampion"},{"key":"ref3","unstructured":"Mor\u00e1n C, Nieto W, Pacheco J. Sarampi\u00f3n en Latinoam\u00e9rica: un an\u00e1lisis de tendencia y red de colaboraci\u00f3n cient\u00edfica en los \u00faltimos 20 a\u00f1os. Rev Cubana Med Trop. 2021;73(2):e545. Disponible en: http:\/\/scielo.sld.cu\/scielo.php?script=sci_arttext&pid=S0375-07602021000200013&lng=es. Epub 01-Ago-2021"},{"key":"ref4","unstructured":"Organizaci\u00f3n Mundial de la Salud. Measles. Ginebra: OMS. Disponible en: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/measles"},{"key":"ref5","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Rub\u00e9ola. Disponible en: https:\/\/www.paho.org\/es\/temas\/rubeola"},{"key":"ref6","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Marco regional para el monitoreo y la reverificaci\u00f3n de la eliminaci\u00f3n del sarampi\u00f3n, la rub\u00e9ola y el s\u00edndrome de rub\u00e9ola cong\u00e9nita en la Regi\u00f3n de las Am\u00e9ricas. Washington, D.C.: OPS; 2022. Disponible en: https:\/\/iris.paho.org\/handle\/10665.2\/56039"},{"key":"ref7","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Actualizaci\u00f3n epidemiol\u00f3gica: sarampi\u00f3n. Washington, D.C.: OPS; 2023. Disponible en: https:\/\/www.paho.org\/es\/documentos\/alerta-epidemiologica-sarampion-20-octubre-2023"},{"key":"ref8","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Alerta epidemiol\u00f3gica: sarampi\u00f3n en la Regi\u00f3n de las Am\u00e9ricas. Washington, D.C.: OPS; 2024. Disponible en: https:\/\/www.paho.org\/sites\/default\/files\/2024-enero-29-phe-alerta-epidemiologica-sarampion-esp-final_0.pdf"},{"key":"ref9","unstructured":"Marranghello L. Sarampi\u00f3n en Costa Rica, evoluci\u00f3n en el siglo XX. Disponible en: https:\/\/repositorio.binasss.sa.cr\/repositorio\/bitstream\/handle\/20.500.11764\/3040\/art2v3n5.pdf"},{"key":"ref10","unstructured":"Ulloa R, Morice A, \u00c1vila ML. El regreso del sarampi\u00f3n. Acta Med Costarric. 2017;59(4):128-129. Disponible en: https:\/\/actamedica.medicos.sa.cr\/index.php\/Acta_Medica\/issue\/view\/90"},{"key":"ref11","unstructured":"Porras O. Vacunaci\u00f3n: esquemas y recomendaciones generales. Acta Pediatr Costarric. 2008;20(2):65-76. Disponible en: https:\/\/www.scielo.sa.cr\/scielo.php?script=sci_arttext&pid=S1409-00902008000200002"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Morice A, Ulloa R, \u00c1vila ML. Congenital rubella syndrome: progress and future challenges. Vaccines. 2009;8(3):323-331. Disponible en: https:\/\/www.researchgate.net\/publication\/24144643_Congenital_rubella_syndrome_Progress_and_future_challenges","DOI":"10.1586\/14760584.8.3.323"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morice A, Carvajal X, Le\u00f3n M, Machado V, Badilla X, Reef S, et al. Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradication: the Costa Rican experience. J Infect Dis. 2003;187(S1):S158-163. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/12721908","DOI":"10.1086\/368053"},{"key":"ref14","unstructured":"Ruiz A. Informe de vigilancia basada en laboratorio: an\u00e1lisis de resultados serol\u00f3gicos e indicadores de calidad del laboratorio para la vigilancia integrada del sarampi\u00f3n-rub\u00e9ola. Costa Rica, enero a diciembre de 2014. Tres R\u00edos: Inciensa; 2015. Disponible en: https:\/\/www.inciensa.sa.cr\/vigilancia_epidemiologica\/informes_vigilancia\/2014\/Virologia\/Informe%20anual%20de%20vigilancia%20basada%20en%20laboratorio%20de%20Sarampion%20y%20Rubeola%20%202014.pdf"},{"key":"ref15","unstructured":"Ruiz A. Informe de vigilancia basada en laboratorio: an\u00e1lisis de resultados serol\u00f3gicos e indicadores de calidad del laboratorio para la vigilancia integrada del sarampi\u00f3n-rub\u00e9ola, Costa Rica, enero a junio de 2015. Tres R\u00edos: Inciensa; 2015. Disponible en: https:\/\/www.inciensa.sa.cr\/vigilancia_epidemiologica\/informes_vigilancia\/2015\/Virologia\/Informe%20de%20vigilancia%20semestral%20de%20sarampion%20y%20rubeola,%20enero%20a%20junio%202015.pdf"},{"key":"ref16","unstructured":"Ruiz A. Informe anual de vigilancia basada en el laboratorio para sarampi\u00f3n y rub\u00e9ola, Costa Rica, 2019. Tres R\u00edos: Inciensa; 2020. Disponible en: https:\/\/www.inciensa.sa.cr\/vigilancia_epidemiologica\/informes_vigilancia\/2020\/Virologia\/INCIENSA%20CNRV-of-2020-073%20Informe%20Anual%20SR%202019.pdf"},{"key":"ref17","unstructured":"Ministerio de Salud P\u00fablica. Autoridades de salud dieron seguimiento de caso de Sarampi\u00f3n en el pa\u00eds. San Jos\u00e9 de Costa Rica: MSP;2024. Disponible en: https:\/\/www.ministeriodesalud.go.cr\/index.php\/prensa\/61-noticias-2024\/1765-autoridades-de-salud-dieron-seguimiento-de-caso-de-sarampion-en-el-pais"},{"key":"ref18","unstructured":"Siemens Healthcare Diagnostics Products. Enzygnost\u00ae Anti-Measles Virus\/IgG. Manual para el usuario. Marburgo: Siemens; 2011:38-46."},{"key":"ref19","unstructured":"Siemens Healthcare Diagnostics Products. Enzygnost\u00ae Anti-Rubella Virus\/IgG. Manual para el usuario. Marburgo: Siemens; 2015:41-49."},{"key":"ref20","unstructured":"Ruiz A. Informe de vigilancia basada en el laboratorio: sarampi\u00f3n y rub\u00e9ola, Costa Rica, enero-diciembre, 2017. Tres R\u00edos: Inciensa; 2018. Disponible en: https:\/\/www.inciensa.sa.cr\/vigilancia_epidemiologica\/informes_vigilancia\/2017\/Virologia\/Informe%20Anual%20de%20laboratorio%20de%20sarampion-rubeola%20%202017.pdf"},{"key":"ref21","unstructured":"Organizaci\u00f3n Mundial de la Salud. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome. Ginebra: OMS; 2018. Disponible en: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/vpd_surveillance\/lab_networks\/measles_rubella\/manual\/chapter-4.pdf"},{"key":"ref22","unstructured":"Virion\/Serion. SERION ELISA classic Masern Virus\/Measles Virus IgG\/IgM. Wurzburgo: Virion\/Serion; 2020. Disponible en: https:\/\/eifu.virion-serion.de\/ivs\/all?keycode=102-16."},{"key":"ref23","unstructured":"Virion\/Serion. SERION ELISA classic R\u00f6teln Virus\/Rubella Virus IgG\/IgM. Wurzburgo: Virion\/Serion; 2020. Disponible en: https:\/\/eifu.virion-serion.de\/ivs\/all?keycode=129-1923."},{"key":"ref24","unstructured":"Conceptualia. Definici\u00f3n y concepto de poblaci\u00f3n econ\u00f3micamente activa. . Disponible en: https:\/\/conceptualia.es\/ciencias-sociales\/demografia\/poblacion-economicamente-activa\/"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Costa-Alcalde JJ, Trastoy-Pena R, Barbeito-Casti\u00f1eiras G, Navarro de la Cruz D, Mejuto B, Aguilera A. Seroprevalencia de anticuerpos frente al virus del sarampi\u00f3n en Galicia: tendencias durante los \u00faltimos diez a\u00f1os en funci\u00f3n de la edad y sexo. Rev Esp Quimioter. 2020;33(2):116-121. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/32118395\/","DOI":"10.37201\/req\/108.2019"},{"key":"ref26","unstructured":"Gil A, Astasio P, Ortega P, Dom\u00ednguez V, Gonz\u00e1lez A. Seroprevalencia de anticuerpos frente a sarampi\u00f3n, rub\u00e9ola, parotiditis y varicela en escolares madrile\u00f1os. An Esp Pediatr. 1999;50(5):459-62. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/10394183\/"},{"key":"ref27","unstructured":"Rodr\u00edguez M, Mart\u00ednez D, Santos J, Borda J, Orero A. Seroprevalencia de sarampi\u00f3n, rub\u00e9ola, paperas y varicela en los trabajadores de un \u00e1rea sanitaria de la Comunidad de Madrid. Rev Esp Quimioter. 2014;27(2):98-101. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/24940889\/"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Andani J, Casta\u00f1eda P, Fuente T, Gim\u00e9nez M, Alcaraz J, G\u00f3mez F, et al. Seroprevalencia frente a sarampi\u00f3n, rubeola y parotiditis en personal facultativo del servicio de pediatr\u00eda del Hospital Universitario y Polit\u00e9cnico La Fe de Valencia. Rev Esp Salud Publica. 2014;88(5):653-659. Disponible en: http:\/\/scielo.isciii.es\/scielo.php?script=sci_arttext&pid=S1135-57272014000500009&lng=es. https:\/\/dx.doi.org\/10.4321\/S1135-57272014000500009","DOI":"10.4321\/S1135-57272014000500009"},{"key":"ref29","unstructured":"Organizaci\u00f3n Mundial de la Salud. Documento de posici\u00f3n de la OMS acerca de las vacunas antisarampionosas. [Internet].Ginebra:OMS; 2017 [Consultado 3 Dic 2023]. Disponible en: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/position-papers\/measles"},{"key":"ref30","unstructured":"Comit\u00e9 Asesor de Vacunas de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Posicionamiento de la OMS sobre la vacunaci\u00f3n contra la rubeola. AEP; 2020. Disponible en: https:\/\/vacunasaep.org\/profesionales\/noticias\/rubeola-posicionamiento-OMS-julio-2020"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Delamater P, Street E, Leslie T, Yang Y, Jacobsen K. Complexity of the basic reproduction number (R0). Emerg Infect Dis. 2019;25(1):1-4. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/30560777\/","DOI":"10.3201\/eid2501.171901"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opin Pharmacother. 2003;4(8):1215-1225. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/12877632\/","DOI":"10.1517\/eoph.4.8.1215.22282"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR. Mahapatro S, Sanmukhani J. Gupta G. Mittal R. Glueck R. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27\/3 rubella strain: results of a randomized, comparative, active controlled phase III clinical trial. Hum Vaccin Immunother. 2017;3;13(7):1523-1530. Disponible en: https:\/\/doi.org\/10.1080\/21645515.2017.1302629","DOI":"10.1080\/21645515.2017.1302629"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Pati\u0107 A, \u0160trbac M, Petrovi\u0107 V, Milo\u0161evi\u0107 V, Risti\u0107 M, Hrnjakovi\u0107 Cvjetkovi\u0107 I, Medi\u0107 S. Seroepidemiological study of rubella in Vojvodina, Serbia: 24 years after the introduction of the MMR vaccine in the national immunization programme. PLoS One. 2020;13;15(1). Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/31929584","DOI":"10.1371\/journal.pone.0227413"},{"key":"ref35","unstructured":"Ribas M, Galindo M, Valc\u00e1rcel M, Garc\u00eda D, Rodr\u00edguez C, Tejero Y. Presencia de anticuerpos a sarampi\u00f3n, rub\u00e9ola y parotiditis en una poblaci\u00f3n cubana de 7 meses a 23 a\u00f1os. Rev Cubana Med Trop. 2004;56(3):192-196. Disponible en: http:\/\/scielo.sld.cu\/scielo.php?script=sci_arttext&pid=S0375-07602004000300007&lng=es."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Xiong Y, Wang D, Lin W, Tang H, Chen S, Ni J. Age-related changes in serological susceptibility patterns to measles: results from a seroepidemiological study in Dongguan, China. Hum Vaccin Immunother. 2014;10(4):1097-03. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4896514\/","DOI":"10.4161\/hv.27734"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Mahallawi W Ibrahim N. Seroprevalence against the measles virus after vaccination or natural infection in an adult population in Madinah, Saudi Arabia. Hum Vaccin Immunother. 2021;17:8. Disponible en: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2021.1876486","DOI":"10.1080\/21645515.2021.1876486"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Dimech W. Mulders M. A 16-year review of seroprevalence studies on measles and rubella. Vaccine. 2016;29(35):4110-4118. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/27340097\/","DOI":"10.1016\/j.vaccine.2016.06.002"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Crooke SN, Haralambieva IH, Grill DE, Ovsyannikova IG, Kennedy RB, Poland GA. Seroprevalence and durability of rubella virus antibodies in a highly immunized population. Vaccine. 2019;37(29):3876-3882. Disponible en: https:\/\/pubmed.ncbi.nlm.nih.gov\/31126859\/","DOI":"10.1016\/j.vaccine.2019.05.049"},{"key":"ref40","unstructured":"Organizaci\u00f3n Mundial de la Salud. Inmunizaci\u00f3n en las Am\u00e9ricas: inmunizaci\u00f3n integral de la familia. Resumen 2021. Washington, D.C.: OPS; 2022. Disponible en: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/55693\/OPSFPLIM210040_spa.pdf?sequence=1&isAllowed=y"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Silva Jr. JB da. La Organizaci\u00f3n Panamericana de la Salud: 120 a\u00f1os promoviendo la salud p\u00fablica en la Regi\u00f3n de las Am\u00e9ricas. Rev Panam Salud Publica.2023;47:e118. Disponible en: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/57762\/V47e1182023.pdf?sequence=1&isAllowed=y","DOI":"10.26633\/RPSP.2023.118"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/62066\/v48e812024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:42:28Z","timestamp":1734349348000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/62066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":41,"alternative-id":["RPSP.2024.81"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2024.81","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}